Rationale: CD40L figures prominently in chronic inflammatory diseases such as atherosclerosis. However, since CD40L potently regulates immune function and hemostasis by interaction with CD40 receptor and the platelet integrin GPIIb/IIIa, its global inhibition compromises host defense and generated thromboembolic complications in clinical trials. We recently reported that CD40L mediates atherogenesis independently of CD40 and proposed Mac-1 as an alternate receptor.
A therosclerosis is a chronic inflammatory disease governed by a network of inflammatory cytokines and immunologic phenomena. 1, 2 CD40L, a member of the tumor necrosis factor superfamily first described on T cells, potently regulates B and T cell function via interaction with its classic receptor CD40. 3 However, expression of CD40L is not confined to T cells but extends to a variety of cell types including those typically resident in atherosclerotic plaques such as endothelial cells (ECs), smooth muscle cells (SMCs), and macrophages. Thus, CD40L has been implicated with a variety of different inflammatory pathologies including atherosclerosis. 4 -7 Functional blockade of CD40L not only reduced atherosclerotic plaque formation and progression, but also attenuated monocyte and lipid content of these lesions while increasing numbers of collagen fibers and SMCs, 6, 8, 9 features associated with more stable plaques in humans. 10 CD40L also augments monocyte/macrophage expression of collagenases implicated in plaque rupture and of tissue factor, a trigger of thrombosis following plaque rupture. Beyond that, CD40L stabilizes thrombi through interaction with the platelet integrin GPIIb/IIIa (␣ IIb ␤ 3 ). 11 While anti-CD40L antibody treatment generated promising results in early clinical trials, elevated thromboembolic complications prohibited the pursuit of this strategy. 11, 12 In addition, long-term inhibition of CD40L-as is most likely required for treatment of chronic inflammatory diseases-severely compromises host defenses, rendering generalized inhibition of CD40L an unappealing treatment strategy.
We previously reported the surprising finding that CD40L promotes atherogenesis without participation of CD40L on bone marrow-derived cells and independently of its classic receptor CD40. 8, 13 These findings point toward a role of CD40L on vascular cells such as ECs or SMCs interacting with an alternate receptor. Indeed, we suggested a novel interaction of CD40L with the leukocyte integrin Mac-1 13 promoting inflammatory cell recruitment, a crucial step in inflammation and atherogenesis. Mac-1 (␣ M ␤ 2 , CD11b/CD18) belongs to the ␤ 2 -family of integrins and functions as adhesive receptor mediating adhesion and transmigration of leukocytes. Mac-1 interacts with a variety of different ligands such as C3bi, 14 ICAM, 15 fibrinogen, 16 fibronectin, 17 heparin, 18 GPIb␣, 19 and RAGE. 20 Thus, Mac-1 has been implicated with immunity, inflammation, and hemostasis. [21] [22] [23] Inhibition of Mac-1 by neutralizing antibodies attenuated atherosclerotic lesion formation in mice by impairing monocyte recruitment. 13 Here, we aimed to characterize the interaction of CD40L and Mac-1 on a molecular level, to design an inhibitory peptide specifically inhibiting this interaction, and to test whether this peptide ultimately limits inflammation and atherogenesis in mice without affecting CD40L's immunologic and thrombotic properties.
Methods
An expanded Methods section is available in the online Data Supplement available at http://circres.ahajournals.org.
Recombinant Protein Expression
Mac-1 I-domain was produced as His-tag fusion protein by inserting the DNA-sequence coding for the Mac-1 amino acids R 115 to S 340 in pET20b (Novagen, Darmstadt, Germany), subsequent purification by Ni-NTA immobilized metal affinity chromatography (Qiagen, Hilden, Germany), and anion-exchange chromatography using Q-Sepharose (GE Healthcare, Sydney, Australia). CD40L was produced as His-and c-myc-tag fusion protein by inserting the coding DNA for amino acids E 108 to L 261 in pHOG-21.
Solid Phase Binding Assay
Recombinant CD40L was incubated with immobilized Mac-1 I-domain in the presence or absence of blocking peptides. Binding of sCD40L was detected by addition of antic-myc-HRP (Invitrogen, Mulgrave, Australia), TMB-substrate (Pierce, Scoresby, Australia), and colorimetric reaction. Alternatively, CD40L (Provitro, Berlin, Germany) was immobilized and binding of the recombinant Mac-1 I-domain was quantified by addition of anti-His-biotin (Qiagen) and HRP-coupled streptavidin (Pierce). For binding to immobilized peptides, CD40L was biotinylated (Micro Biotinylation Kit, Sigma, St. Louis, MO).
Surface Plasmon Resonance
Binding was characterized on a BIAcore 3000 (BIAcore AB, GE Healthcare) by amine coupling of CD40L or Mac-1 I-domain onto a CM5 sensor chip. Experiments were performed by passing sample solutions over the receptor coated and reference flow cells at RT in PBS ϩ0.1% BSA at the flow rate 20 L/min. Surfaces were regenerated by 30-s pulses of 5 mmol/L NaOH. Kd values were calculated using the kinetic rate constants using the software provided by the manufacturer.
Dynamic and Static Adhesion Assays
We coated 96-well plates (Nunc, New York, NY) with sCD40L and incubated with CHO cells expressing constitutively activated Mac-1, or THP-1 cells. HEK 293-cells expressing wildtype or chimeric ␤ 2 -integrins have been previously described and have been used as indicated. 24 Briefly, cells were allowed to adhere for 20 to 50 minutes. Cells were preincubated with blocking antibodies (10 g/mL) or peptides (50 mol/L) as indicated. Permeabilization buffer (6 mg/mL phosphatase substrate (Sigma), 1% Triton X-100, 50 mmol/L sodium acetate, pH 5.5) was added for colorimetric quantification. Alternatively, adhering cells were counted or stained for detection in fluorometer. For dynamic adhesion assays, 35-mm dishes or glass capillaries were coated with 1% BSA, CD40L, GPIb␣ (Abnova, Heidelberg, Germany), fibrinogen (Sigma), or ICAM-1 (R&D Systems, Minneapolis, MN). Adhering and rolling cells were quantified in a parallel flow chamber system (Glycotech, Gaithersburg, MD) at the indicated shear rates and in the presence of the indicated peptides (1 mol/L) or antibodies (10 g/mL).
Flow Cytometry
Quantification of leukocyte subsets was performed by flow cytometry. Binding of cM7 to CD40L-expressing Murine fibroblasts was determined by quantification of FITC-coupled cM7. Binding of CD40L to Mac-1 expressing CHO-cells or human leukocytes was performed by incubation with CD40L (10 g/mL) and subsequent detection with antipenta-His antibody (Qiagen).
Serum Cytokines
Plasma concentrations of cytokines and chemokines were determined by cytometric bead array (BD Biosciences, San Jose, CA).
Pharmacokinetics
C57BL/6J mice received intraperitoneal injections with FITC or TAMRA-labeled peptides cM7 or scM7. Fluorescence in plasma samples was measured at indicated time points. Endothelial binding was visualized by intravital microscopy.
Murine Peritonitis
WT or CD40L Ϫ/Ϫ mice (Jackson Laboratories, Bar Harbor, ME) received an injection of 3 mL of 4% thioglycollate broth (Sigma). A peritoneal lavage was performed after 15 hours. Peritoneal exudate cells (PECs) were quantified after red cell lysis. 
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Intravital Microscopy
Mice received intraperitoneal injections of 200 ng of Murine TNF␣ (R&D Systems) and 100 g of peptides 5 hours before surgery. Mice were anesthetized by intraperitoneal injection of ketamine hydrochloride (Essex) and xylazin (Bayer, Leverkusen, Germany). The cremaster muscle was exteriorized. Videos were taken with an intravital microscope (AxioScope Vario, Carl Zeiss, Sydney, Australia) fitted with a saline immersion objective (WPlan-APOCHROMAT 20x/1,0DIC IR, Carl Zeiss). Rolling leukocyte flux was defined as the number of leukocytes moving at a velocity less than erythrocytes. Adherent leukocytes were defined as cells that remained stationary for at least 30 s.
Atherogenesis Study
Eight-week-old male LDL-receptor-deficient (LDLr Ϫ/Ϫ ) mice (Jackson Laboratories) consuming a high-cholesterol diet (HCD) for 20 weeks were treated with intraperitoneal injections of the peptides cM7, scM7 (100 g), or sterile saline 3 times a week. Atherosclerotic lesions were analyzed histologically as described previously. 8, 13 In Vivo Thrombosis Model Three-to 4-week-old C57BL/6J mice received intraperitoneal injections of either sterile saline (100 L), the peptides cM7, scM7, or the indicated antibodies. A mesenteric arteriole was chosen and injured with ferrichloride. Platelets were stained by retro-orbital injection of rhodamine 3G and visualized through an intravital microscope (AxioScope Vario, Carl Zeiss). Vessel occlusion time and thrombus embolization rate was analyzed. Tail bleeding time was determined as previously reported. 11
Structural Modeling
Mac-1 I-domain structure was visualized using Sirius visualization system 1.2 (San Diego Supercomputer Center) and a crystallographic dataset for the Mac-1 I-domain (PDB ID: 1NA5).
Statistical Analysis
Data are presented as meanϮSEM. Statistical testing employed Student unpaired t test or analysis of variance (ANOVA), followed by Newman-Keuls post hoc test or Mann-Whitney U test as indicated. Probability values Ͻ0.05 were considered significant.
Results
CD40L Concentration-Dependently Binds to the Mac-1 I-Domain
Since most of Mac-1's ligands-such as fibrinogen, ICAM-1, GPIb␣, RAGE, C3bi, or heparin-bind to the Mac-1 I-domain, 18 -20,25,26 a stretch of Ϸ220 amino acids within the ␣ M subunit of the integrin, we hypothesized that the I-domain also serves as binding partner for CD40L. As expected, ␣ M ␤ 2 (Mac-1) expressing HEK cells strongly adhered to CD40L while HEK cells expressing the ␣ L ␤ 2 integrin (LFA-1) failed to mediate cell adhesion. However, binding of HEK cells expressing ␣ L ␤ 2 to CD40L could be rescued when the ␣ M I-domain replaced the ␣ L I-domain in the ␣ L ␤ 2 backbone, demonstrating that CD40L binds to Mac-1's I-domain ( Figure 1A) . Figure 1C ,D). Interestingly, the Mac-1 antibody clone 2LPM19c blocked adhesion of Mac-1expressing CHO cells to fibrinogen only while both antibody clones, ICRF44 and 2LPM19c, abrogated adhesion of these cells to CD40L, suggesting that CD40L binds to the I-domain, but to a binding site distinct from that of fibrinogen (Supplemental Figure IIc , IId). Anti-CD40L treatment abrogated adhesion to CD40L but not to fibrinogen, indicating specificity of the assay.
The EQLKKSKTL Motif Within Mac-1's I-Domain Serves as Binding Site for CD40L
To identify the binding site used by CD40L, we employed a peptide mapping strategy using a set of linear peptides, M1-M8, originating from the hydrated surface of Mac-1's I-domain (Supplemental Table I , Figure 2A ), 19 as competitive inhibitors of the CD40L/Mac-1 dyad. In an initial solid phase binding assay evaluating the binding of the isolated Mac-1 I-domain to immobilized CD40L, the peptides M3, M4, M5, and M7 emerged as potential candidate inhibitors (data not shown). In the more physiological setting with the entire Mac-1 protein in a cell membrane environment, peptide M7, mimicking the EQLKKSKTL motif (E 162 -L 170 ), most efficiently blocked adhesion of THP-1 cells to CD40L (61%Ϯ3% inhibition, nϭ3, Pϭ0.003). The extent of inhibition resembled that of a pan I-domain blocking antibody (57%Ϯ24% inhibition, nϭ3, Pϭ0.03, Figure 2B ). In accord, only M7 blocked binding of fluorescence-labeled CD40L to Mac-1 expressing human granulocytes and monocytes in flow cytometry (54%Ϯ11% inhibition, nϭ3, Pϭ0.001, Figure 2C) . Also, biotinylated CD40L specifically bound to immobilized peptide M7 ( Figure 2D ). To provide genetic proof of involvement of the EQLKKSKTL motif, we tested adhesion of HEK cells expressing either wildtype ␣ M or chimeric ␣ M integin backbones substituted with the ␣ L I-domain sequences E 162 -L 170 or E 178 -T 185 corresponding to the sequences of M7 and M8, respectively. Consistent with our previous findings, switch of the EQLKKSKTL motif abrogated adhesion on CD40L while switch of the sequence EEFRIHFT (E 178 -T 185 , M8) had no effect ( Figure 2E ). Interestingly, adhesion to the fibrinogen recognition peptide, P2-C, was enhanced by deletion of the CD40L-binding site (data not shown) as reported previously. 28 Finally, M7 concentration-dependently inhibited binding of CD40L to Mac-1 in a solid phase binding assay and in SPR-analysis (IC50 of 200 -900 nmol/L) (Supplemental Figure III ).
The Peptide Inhibitor cM7 Is Available in Plasma and Specifically Interferes With CD40L-Mac-1 Binding
Therapeutic application of peptides in vivo requires adequate plasma availability. To improve plasma stability and resistance to degradation by peptidases, we modified the peptide M7 by addition of 2 flanking cysteine residues C-and N-terminal and subsequent cyclization by disulfide-bonds (termed cM7). A scrambled peptide, scM7, served as control for subsequent in vivo experiments ( Supplemental Table I ).
In accord with previous reports using cysteine-cyclized peptides, 29 cM7 coupled to fluorescein isothiocyanate (FITC) persisted in plasma between 30 minutes and 4 hours with the highest plasma availability at 30 minutes after intraperitoneal injection (12.2Ϯ0.8 mol/L versus 15.8Ϯ1.6 mol/L for 100 g and 200 g cM7, respectively, Supplemental Figure IVa) . Notably, FITC-labeled cM7 concentration-dependently bound to Murine fibroblasts overexpressing CD40L, but not to respective mock-transfected control cells (Supplemental Figure IVb) . After intraperitoneal injection, fluorescent cM7, but not scM7, bound to inflamed endothelium in intravital microscopy (Supplemental Figure IVc) . To assess specificity of the peptide inhibitor cM7, we tested the adhesion of Mac-1-CHO cells to different immobilized Mac-1 ligands in the flow chamber. While cM7 concentration dependently blocked cellular adhesion to CD40L with an IC50 of 206 nmol/L ( Figure 3A, 3B) , it did not affect adhesion to ICAM-1 and GPIb␣ ( Figure 3C, 3D) . In contrast, peptide M2 blocked the interaction between Mac-1 and GPIb␣ as described previously, while not affecting CD40L-Mac-1 binding. 19 Finally, cM7 did not alter binding of CD40 to CD40L, whereas pretreatment with anti-CD40 concentration- dependently blocked receptor-ligand interaction in a solid phase binding assay ( Figure 3E ).
The CD40L-Mac-1 Interaction Drives Leukocyte Recruitment in Vitro and in Vivo
Mac-1 potently regulates cell adhesion and migration. 22, 23 We previously demonstrated that an anti-Mac-1-pan-I-domain blocking antibody limits thioglycollate-induced leukocyte recruitment to the peritoneal cavity while in turn injection of CD40L promoted peritoneal inflammation, suggesting that CD40L may contribute to leukocyte recruitment via Mac-1. 13 Consequently, we tested whether selective inhibition of the CD40L-Mac-1 by our peptide inhibitor would effectively limit peritoneal inflammation. Indeed, treatment with cM7 significantly decreased thioglycollate-elicited peritoneal exudate cell (PEC) accumulation in wildtype mice by 50Ϯ8% compared to scM7 (nՆ6, Pϭ0.01). Of note, treatment with cM7 had no effect in CD40L Ϫ/Ϫ and Mac-1 Ϫ/Ϫ mice, suggesting that our peptide antagonist cM7 required presence of CD40L and acted specifically ( Figure 4A ). Notably, total numbers of PECs were higher in saline-treated Mac-1 Ϫ/Ϫ as previously reported 30 (Supplemental Figure V) . Since Mac-1 classically functions as adhesive receptor in a variety of pathologies, we tested the functional role of the CD40L/ Mac-1 interaction in inflammatory cell recruitment in intravital microscopy. Injection of cM7 but not scM7 significantly reduced rolling and adhesion by 40%Ϯ11% (nՆ9, Pϭ0.03 versus scM7) and 24%Ϯ7% (nՆ9, Pϭ0.03 versus scM7), respectively, in cremaster vessels of mice challenged with TNF␣ ( Figure 4B through 4D, Supplemental Videos I through III). Average rolling velocity was not changed ( Figure 4E ). Possible confounders, such as blood pressure, average vessel diameter, leukocyte, or platelet counts did not change between cM7-and scM7-treated mice ( Supplemental  Table II ). Interestingly, in a second set of mice cM7 reduced rolling cell flux within minutes after intravenous delivery (Supplemental Figure VI) , suggesting direct modulation of the leukocyte adhesion cascade rather than regulating adhesion molecule expression.
In vitro, adhesion of Mac-1 expressing Chinese hamster ovarian cells (CHO) to TNF␣-activated human ECs could be inhibited by selective antibodies blocking CD40L on EC or Mac-1 on CHO cells but not vice versa, rendering direct interaction between endothelial CD40L and leukocyte Mac-1 most likely (Supplemental Figure VIIa) . Anti-CD40L treatment blocked adhesion to the same extent as did treatment with anti-ICAM-1 or anti-Mac-1, suggesting biological relevance of this interaction (Supplemental Figure VIIb) . ECs deficient for CD40L, showed significantly decreased adhering and rolling of leukocytes in the flow chamber compared with CD40L-competent EC (Supplemental Figure VIIc, VIId) while expressing similar amounts of the endothelial adhesion molecules ICAM-1, -2, VCAM-1, and P-Selectin (Supplemental Figure VIIe) . Platelet-leukocyte interactions critically participate in inflammation 31 and CD40L expression is up-regulated on activated platelets. 32 However, in vitro and in vivo, inhibition of either total CD40L with blocking antibodies and by cM7 did not modulate platelet-leukocyte adhesion and aggregation formation (Supplemental Figure VIII) . Also, CD40L/Mac-1 interaction did not induce inflammatory gene expression, MAP kinase-, or NFB-activation in human monocytes and murine leukocytes (Supplemental Figure IX) .
Specific Blockade of the CD40L-Mac-1 Interaction Attenuates Atherosclerosis in Mice
Inflammatory cell recruitment contributes critically to the initiation and progression of various chronic inflammatory diseases inclucing atherosclerosis. 2 Therefore, we tested whether specific inhibition of the CD40L/Mac-1 interaction mitigated atherosclerosis in mice. LDLr Ϫ/Ϫ mice consuming a high-cholesterol diet for 20 weeks developed significantly smaller lesions in the aortic sinus (reduction by 21%Ϯ6% L (B through D) , or a scrambled control peptide (scM7). M2 (12.5 mol/L) represents a GPIb␣-specific peptide (D). CD40L (10 g/mL) was preincubated with different concentrations of cM7 and scM7 (10, 50, or 100 mol/L) or a blocking anti-CD40 antibody (10, 20, or 50 g/mL) and was subsequently incubated with immobilized CD40-Fc fragments (5 g/mL). Binding of CD40L to CD40 was quantified by colorimetric reaction (F). Data are presented as meanϮSEM of at least 3 independent experiments.
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versus scM7, nՆ11, Pϭ0.03) and by tendency also in abdominal aortas (reduction by 30%Ϯ10% versus scM7, nՆ9, Pϭ0.056) when treated with cM7 compared with scM7-treated controls ( Figure 5A, 5B) . Beyond a mere reduction in size, atherosclerotic plaques from cM7-treated animals contained significantly fewer macrophages (decrease by 37%Ϯ6% versus scM7, nՆ10, PϽ0.001, Figure 6B ) and lower amounts of lipids (reduction by 32%Ϯ5% versus scM7, nՆ11, PϽ0.001, Figure 6A ). In contrast, number of smoothmuscle cells (SMCs) were unchanged compared with salinetreated mice but increased by 88%Ϯ26% compared with scM7 treatment (nՆ11, PϽ0.01, Figure 6C ), while infiltra-tion of neutrophils was overall low and not changed within the groups (Supplemental Figure X) . Collagen content increased in plaques of both, the treatment and the control group ( Figure 6D ). However, plaques from cM7-treated animals contained more stable collagen fibers (increase by 38%Ϯ9% versus scM7, nՆ11, Pϭ0.014, Figure 6e , Supplemental Figure X) . Thus, features of plaques from cM7-treated animals resembled those of more stable plaques in humans. Importantly, lipid levels and weights remained unchanged between cM7 and scM7-terated mice (Table) . Presence of CD40L is critical for T-cell function, proliferation, and expression of T-cell-specific cytokines. [33] [34] [35] [36] However, we did barϭ1000 m (A, B) .
not observe changes in cytokine profiles indicative of a switch in Th1-/Th-2 phenotype or T-cell subsets on long-term treatment with cM7 in mice of the atherogenesis study (Supplemental Figure XI) .
CD40L-Mac-1 Interaction Does Not Affect Bleeding Time and Thrombus Formation in Mice
Hemostatic functioning of CD40L depends on interaction with either CD40 or platelet integrin GPIIb/IIIa (␣ IIb ␤ 3 ). 11, 37 The inhibition of this interaction by former therapeutic strategies employing antibodies neutralizing total CD40L provoked thromboembolic complications. Thus, confirming previous studies, treatment with an anti-CD40L blocking antibody significantly prolonged tail vein bleeding time by 74%Ϯ12% (nՆ4, Pϭ0.04) in our study. Interestingly, selective blockade with cM7 did not modulate platelet activation (Supplemental Figure VIIIb) and bleeding time ( Figure 7A ), suggesting that CD40L-Mac-1 interaction is specific for CD40L's inflammatory pathways. Accordingly, cM7 did not prolong vessel occlusion time in a model of arterial thrombosis (Supplemental Videos IV through X), whereas anti-CD40L and anti-CD40 treatment impaired thrombus formation in mesenterial arterioles resulting in a prolongation of the occlusion time by 113%Ϯ22% (nϭ5, Pϭ0.005) and 116%Ϯ22% (nϭ4, Pϭ0.05), respectively ( Figure 7B ). Furthermore, disruption of the CD40L-Mac-1 interaction by cM7 only caused a slight increase in thromboembolization rate (by 67%Ϯ15%, nϭ5, Pϭ0.005). However, this was a negligible effect compared with anti-CD40L and anti-CD40 treatment increasing embolization rate by 339%Ϯ38% (nϭ6, Pϭ0.001), and 173%Ϯ40% (nϭ3, Pϭ0.008), respectively. Interestingly, treatment with neutralizing anti-Mac-1 antibodies also increased the embolization rate-albeit mildly-by 131%Ϯ41% (nϭ4, Pϭ0.03, Figure 7C, 7D ).
Discussion
We previously made the surprising observation that CD40L binds to the leukocyte integrin Mac-1 and proposed this new interaction as alternative pathway for CD40L-mediated inflammation. 13 In the present study, we characterized the CD40L-Mac-1 interaction on a molecular level and demonstrated that CD40L specifically binds to a distinct region within Mac-1's I-domain revealing a high-affinity interaction comparable with that of CD40L's interaction with ␣ IIb ␤ 3 . 11 Our plasmon resonance data suggest a binding affinity in the range of 200 nmol/L of the ␣ M I-domain for CD40L, which is about 10-fold lower than the classical interaction between CD40L and CD40 as reported previously. 38 However, since it is known that integrin activity is regulated by inflammation, it is likely that the binding affinity between CD40L and Mac-1 regionally is much higher and could be further enhanced by additional interactions between CD40L and other regions of Mac-1 outside of the ␣ M I-domain. Also, binding affinity of CD40L was Ϸ3-fold higher to the immobilized, oligomerized ␣ M I-domain, suggesting that integrin clustering might critically strengthen binding as reported previously. 39 Employing a peptide-mapping strategy, we identified the motif EQLKKSKTL within Mac-1's I-domain as a site involved in binding of CD40L. Our data-that chimeric ␣ M integrin in which the ␣ L I-domain sequence corresponding E 162 -L 170 did not bind CD40L-strongly suggest that the EQLKKSKTL motif in fact represents a critical binding sequence. However, we cannot rule out that EQLKKSKTL is only part of the binding sequence or modulates binding affinity as previously observed for other Mac-1 ligands. 24 Also, other segments of the integrin within or outside of the the ␣ M I-domain could be involved. A systematic mutational analysis will have to be undertaken to address these questions in the future. We further demonstrated that small peptide inhibitors mimicking this sequence, M7 or cM7, its cyclisized version, selectively blocked binding of CD40L to Mac-1. In solid phase binding assays and cellular adhesion assays, the IC50 ranged between 200 and 900 nmol/L. However, cM7 did not affect some of the other receptor-ligand interactions described previously for both proteins. This is in accordance with Ustinov et al, who proposed a mosaic binding model with distinct or overlapping regions within the I-domain as potential binding sites. 40 Interestingly, the region corresponding to M7 (E 162 -L 170 ), located on an exposed loop between the ␣1 helix and ␤-sheet B in the tertiary structure of the I-domain, has not been implicated in binding of GPIb␣, NIF, C3bi, ICAM-1, or fibrinogen to Mac-1 ( Figure 2B ). 19, 26, [41] [42] [43] The peptide cM7 blocked the interaction of CD40L to Mac-1 while leaving the interactions of Mac-1 with GPIb␣, ICAM-1, and fibrinogen unaffected. These data corroborate the concept that CD40L binds to a unique binding site on Mac-1. CD40L itself has at least 4 different receptors, including CD40, GPIIb/IIIa (␣ IIb ␤ 3 ) , Mac-1 (␣ M ␤ 2 ), and ␣ 5 ␤ 1 44 . Binding of CD40 to CD40L was previously mapped to CD40L's amino residues K 143 , R 203 , G 220 , Y 145 , and Y 146 . 45, 46 Andre et al showed that binding of GPIIb/IIIa to CD40L involved CD40L's KGD 115-117 sequence. 11 Whether binding of Mac-1 to CD40L also occurs at a distinct region within CD40L needs to be verified by future studies. However, our data strongly suggest this notion: we show (1) that M7 and cM7 bind to CD40L, (2) that cM7 does not affect binding of CD40L to CD40, and (3) that cM7 does not affect bleeding time and thrombus formation-CD40L's hemostatic functions, which have been shown to be dependent on interactions with both CD40 and GPIIb/IIIa. These findings support the notion of specific binding sites for the CD40L-Mac-1 interaction on both interaction partners.
We and others previously implicated CD40L in leukocyte recruitment in inflammatory disease including atherosclerosis. 6, 8 In line with this concept, cM7 effectively limited recruitment of inflammatory cells to the peritoneal cavity and the endothelium in vivo, demonstrating that CD40L mediates inflammatory cell recruitment by interaction with the EQLKKSKTL motif on Mac-1. Mac-1 participates in inflammation as adhesion receptor, efficiently promoting both firm adhesion and slow rolling of leukocytes. 15, 47 While this effect was thought to be solely dependent on the binding of Mac-1 to endothelial ICAM-1, Lo et al proposed the existence of an alternative endothelial ligand for Mac-1. 48 In accord, Lauterbach et al observed that the adhesion of neutrophils in intravital microscopy was more severely impaired in ICAM-1-Mac-1 double knock-out mice than in mice deficient in either of these factors alone. 49 CD40L could be such an alternative endothelial binding partner for Mac-1. Since platelet depositions occur at sites of inflamed EC, 31 the interaction of leukocyte Mac-1 with platelets expressing CD40L could also contribute to the effects observed in our study. However, this is unlikely since we did not observe modulation of platelet activation or monocyte platelet aggregate formation by cM7. Interestingly, cM7 treatment also resulted in attenuated expression of TNF␣ and MCP-1 in a Murine cytokine challenge model, but cM7 did not modulate inflammatory signaling and gene expression in cell culture ex vivo. These data suggest that cM7 does not modulate outside in signaling via Mac-1 but may rather affect inflammatory gene expression in vivo via secondary mechanisms, eg, reduced leukocyte recruitment.
Since the recruitment of monocytes is considered a crucial step in the initiation and progression of atherosclerosis, 2 we tested whether specific disruption of the CD40L-Mac-1 dyad would ultimately limit the development of atherosclerotic lesions in vivo. Treatment with cM7 resulted in significantly smaller, less inflamed, and potentially more stable atherosclerotic lesions. These findings agree with previous reports by us and others demonstrating that genetic deficiency or unselective inhibition of CD40L by neutralizing antibodies attenuates atherosclerotic lesion formation and favorably affects plaque mor-phology. 5, 6, 9 Beyond that, our data illustrate for the first time that CD40L's interaction with a distinct region on Mac-1's I-domain mediates its proatherogenic properties. While impaired migration of monocytes to atherosclerotic lesions may in fact be explained by the anti-inflammatory, antiadhesive effects of cM7, the increased number of SMCs and stable collagen fibers after CD40L-Mac-1 blockade needs to be further explored. Since SMCs express CD40L, 50 a cross-talk between SMCs and macrophages mediated by the CD40L/Mac-1 interaction might explain this effect.
While inflammation drives many chronic diseases including atherosclerosis, few selective anti-inflammatory treatment options currently exist. In the context of atherosclerosis, statins allow a glimpse at the therapeutic potential of such strategies. 51 Also cox-2 inhibitors exemplify the impressive therapeutic benefits but also the difficulty in developing anti-inflammatory drugs without side effects. 52 Our peptide-based strategy might overcome some of these limitations. Also, cM7 attenuated inflammation and atherogenesis rather than abrogating it completely. In fact, a more subtle inhibition of inflammatory activity may be actually the more promising and fruitful strategy in the combat of atherosclerosis where most likely long-term therapy is needed and inflammatory regenerative pathways should stay intact. Our data add a new dimension to the understanding of CD40L-mediated inflammation-for long thought to be solely dependent on the interaction with its classical receptor CD40. Our findings might revive the concept of a therapeutic blockade of CD40L. Previous concepts aimed at the global inhibition of Figure 7 . CD40L-Mac-1 interaction does not mediate thrombus formation and stability in mice. C57Bl/6 wildtype mice were injected with the peptides cM7, scM7 (100 g), blocking antibodies against Mac-1, CD40L, CD40 (100 g), IgG isotype control (100 g), or saline, before assessment of tail bleeding time (A) and in vivo thrombus formation (B through D) in mesenteric arterioles following injury with ferrichloride. Thromboembolization rate was defined as frequency of emboli per minute (C, D). Data are presented as meanϮSEM of at least 4 animals per group. Scale barϭ200 m.
CD40L and failed due to acute or long-term side effects. In particular, clinical data revealed thromboembolic complications most likely due to destabilization of thrombi. 11 In accord, we show that inhibition of CD40L and CD40 prolonged bleeding time, inhibited thrombus formation, and promoted thrombus destabilization. In contrast, specific inhibition of the CD40L-Mac-1 interaction hardly affected thrombus integrity. Moreover, cM7 did not interfere with CD40-CD40L binding in vitro and did not induce changes in basic immunologic characteristics such as alteration of Th1/Th2-phenotype as previously demonstrated for CD40L-CD40-signaling. 3 Taken together, these findings suggest the following scenario: CD40L mediates its inflammatory actions preferably via the CD40L-Mac-1 dyad, whereas its immunologic and thrombotic features rather depend on its interaction with CD40 and GPIIb/IIIa. Indeed, the use of selective strategies to block CD40L's interaction partners as suggested in this work might enable development of tailored drugs for different CD40L-dependent conditions. The peptide inhibitor cM7 effectively and specifically inhibited CD40L-Mac-1-dependent inflammatory cell recruitment and atherogenesis. Therefore, selective inhibition of the CD40L-Mac-1 interaction as achieved by cM7 treatment in this study may represent a fruitful novel strategy to combat chronic inflammatory diseases such as atherosclerosis.
